{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,23]],"date-time":"2025-12-23T19:37:20Z","timestamp":1766518640693,"version":"3.48.0"},"reference-count":47,"publisher":"BMJ","issue":"6935","license":[{"start":{"date-parts":[[1994,4,16]],"date-time":"1994-04-16T00:00:00Z","timestamp":766454400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.bmj.com\/company\/legal-information\/terms-conditions\/legal-information\/tdm-licencepolicy"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["BMJ"],"published-print":{"date-parts":[[1994,4,16]]},"DOI":"10.1136\/bmj.308.6935.1033","type":"journal-article","created":{"date-parts":[[2011,10,27]],"date-time":"2011-10-27T19:21:28Z","timestamp":1319743288000},"page":"1033-1036","source":"Crossref","is-referenced-by-count":26,"title":["Current Issues in Cancer: Multiple myeloma"],"prefix":"10.1136","volume":"308","author":[{"given":"I C M","family":"MacLennan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M","family":"Drayson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J","family":"Dunn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[1994,4,16]]},"reference":[{"unstructured":"Office of Population Censuses and Surveys .Mortality statistics, cause, 1991.London: HMSO,1992:18. (Series DH2.)","key":"2025122310090516000_308.6935.1033.1"},{"doi-asserted-by":"publisher","key":"2025122310090516000_308.6935.1033.2","DOI":"10.1136\/jcp.37.8.852"},{"doi-asserted-by":"publisher","key":"2025122310090516000_308.6935.1033.3","DOI":"10.1136\/bmj.288.6428.1411"},{"key":"2025122310090516000_308.6935.1033.4","doi-asserted-by":"crossref","first-page":"47","DOI":"10.7326\/0003-4819-96-1-47","article-title":"Biphasic pattern of bacterial infection in multiple myeloma","volume":"96","author":"Savage","year":"1982","journal-title":"Ann Intern Med"},{"doi-asserted-by":"publisher","key":"2025122310090516000_308.6935.1033.5","DOI":"10.1056\/NEJM198006123022405"},{"key":"2025122310090516000_308.6935.1033.6","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1182\/blood.V62.1.166.166","article-title":"Clinical, morphological, and cell kinetic differences among multiple myeloma, monoclonal gammopathy of undetermined significance and smouldering multiple myeloma","volume":"62","author":"Greipp","year":"1983","journal-title":"Blood"},{"key":"2025122310090516000_308.6935.1033.7","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1111\/j.1365-2141.1984.tb06116.x","article-title":"Low plasma cell 3(H) thymidine incorporation in monoclonal gammopathy of undetermined significance (MGUS), smouldering myeloma and remission phase myeloma: a reliable indicator of patients not requiring therapy","volume":"58","author":"Boccadoro","year":"1984","journal-title":"Br J Haematol"},{"doi-asserted-by":"publisher","key":"2025122310090516000_308.6935.1033.8","DOI":"10.1056\/NEJM199110313251802"},{"key":"2025122310090516000_308.6935.1033.9","doi-asserted-by":"crossref","first-page":"1492","DOI":"10.1200\/JCO.1992.10.9.1492","article-title":"Phase I study of busulfan and cyclophosphamide in preparation for allogeneic marrow transplant for patients with multiple myeloma","volume":"10","author":"Bensinger","year":"1992","journal-title":"J Clin Oncol"},{"key":"2025122310090516000_308.6935.1033.10","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/S0889-8588(18)30354-X","article-title":"Allogeneic bone marrow transplantation in multiple myeloma","volume":"6","author":"Tura","year":"1992","journal-title":"Hematol Oncol Clin North Am"},{"key":"2025122310090516000_308.6935.1033.11","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1038\/bjc.1989.22","article-title":"Reassessment of the relationship between M-protein decrement and survival in multiple myeloma","volume":"59","author":"Palmer","year":"1989","journal-title":"Br J Cancer"},{"doi-asserted-by":"publisher","key":"2025122310090516000_308.6935.1033.12","DOI":"10.1002\/1097-0142(19910701)68:1<62::AID-CNCR2820680112>3.0.CO;2-6"},{"key":"2025122310090516000_308.6935.1033.13","first-page":"59","article-title":"Multiple myeloma: plateau phase revisited","volume":"5","author":"Joshua","year":"1991","journal-title":"Haematology Reviews"},{"key":"2025122310090516000_308.6935.1033.14","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1182\/blood.V30.1.74.74","article-title":"Melphalan in multiple myeloma","volume":"30","author":"Hoogstraten","year":"1967","journal-title":"Blood"},{"key":"2025122310090516000_308.6935.1033.15","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1182\/blood.V31.1.1.1","article-title":"Melphalan therapy for plasma cell myeloma","volume":"31","author":"Alexanian","year":"1968","journal-title":"Blood"},{"doi-asserted-by":"publisher","key":"2025122310090516000_308.6935.1033.16","DOI":"10.1016\/0140-6736(92)90004-M"},{"key":"2025122310090516000_308.6935.1033.17","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1200\/JCO.1992.10.2.334","article-title":"Combination chemotherapy versus melphalan and prednisolone in the treatment of multiple myeloma: an overview of published trials","volume":"10","author":"Gregory","year":"1992","journal-title":"J Clin Oncol"},{"doi-asserted-by":"publisher","key":"2025122310090516000_308.6935.1033.18","DOI":"10.1002\/hon.2900060216"},{"key":"2025122310090516000_308.6935.1033.19","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1002\/hon.2900060213","article-title":"Prognostic factors and staging systems for multiple myeloma: comparisons between the Medical Research Council studies in the United Kingdom and the Southwest Oncology Group studies in the United States","volume":"6","author":"Kelly","year":"1988","journal-title":"Hematol Oncol"},{"doi-asserted-by":"publisher","key":"2025122310090516000_308.6935.1033.20","DOI":"10.1038\/bjc.1976.220"},{"doi-asserted-by":"publisher","key":"2025122310090516000_308.6935.1033.21","DOI":"10.1038\/bjc.1977.1"},{"key":"2025122310090516000_308.6935.1033.22","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/bjc.1985.140","article-title":"Cooper EH, MacLennan ICM. The prognostic value of serum (Beta)2 microglobulin compared with other presentation features in myelomatosis. (A report to the Medical Research Council's Working Party on Leukaemia in Adults.)","volume":"52","author":"Cuzick","year":"1985","journal-title":"Br J Cancer"},{"key":"2025122310090516000_308.6935.1033.23","first-page":"926","article-title":"Doxorubicin\/BCNU chemotherapy for multiple myeloma in relapse","volume":"i","author":"Alberts","year":"1975","journal-title":"Lancet"},{"key":"2025122310090516000_308.6935.1033.24","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1200\/JCO.1986.4.8.1227","article-title":"Improved survival duration with combination chemotherapy induction for multiple myeloma. A South West Oncology Group Study","volume":"4","author":"Durie","year":"1986","journal-title":"J Clin Oncol"},{"key":"2025122310090516000_308.6935.1033.25","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1200\/JCO.1991.9.3.444","article-title":"Multiple myeloma: VMCP\/ VBAP alternating chemotherapy is not superior to melphalan and prednisone even in high risk patients","volume":"9","author":"Boccadoro","year":"1991","journal-title":"J Clin Oncol"},{"key":"2025122310090516000_308.6935.1033.26","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1200\/JCO.1993.11.6.1165","article-title":"Alternating combination VCMP\/VBAP chemotherapy versus melphalan\/ prednisone in the treatment of multiple myeloma: a randomized multicentric study of 487 patients","volume":"11","author":"Blade","year":"1993","journal-title":"J Clin Oncol"},{"key":"2025122310090516000_308.6935.1033.27","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1111\/j.1365-2141.1990.tb02564.x","article-title":"Initial treatment in multiple myeloma: no advantage of multi-drug chemotherapy over melphalan- prednisolone","volume":"74","author":"Hjorth","year":"1990","journal-title":"Br J Haematol"},{"key":"2025122310090516000_308.6935.1033.28","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1038\/bjc.1985.171","article-title":"Objective evaluation of the role of vincristine in induction and maintenance therapy for myelomatosis","volume":"52","year":"1985","journal-title":"Br J Cancer"},{"key":"2025122310090516000_308.6935.1033.29","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1056\/NEJM198405243102104","article-title":"Effective treatment of advanced multiple myeloma refractory to alkylating agents","volume":"310","author":"Barlogie","year":"1984","journal-title":"N Engl J Med"},{"key":"2025122310090516000_308.6935.1033.30","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1002\/hon.2900070107","article-title":"Pulsed high dose oral prednisolone in relapsed or refractory multiple myeloma","volume":"7","author":"Norfolk","year":"1989","journal-title":"Hematol Oncol"},{"key":"2025122310090516000_308.6935.1033.31","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1002\/ajh.2830360303","article-title":"High-dose dexamethasone for refractory or relapsing multiple myeloma","volume":"36","author":"Friedenberg","year":"1991","journal-title":"Am J Hematol"},{"doi-asserted-by":"publisher","key":"2025122310090516000_308.6935.1033.32","DOI":"10.1002\/ajh.2830330203"},{"doi-asserted-by":"publisher","key":"2025122310090516000_308.6935.1033.33","DOI":"10.1001\/archinte.1975.00330010149019"},{"key":"2025122310090516000_308.6935.1033.34","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1002\/hon.2900060215","article-title":"Results of the MRC myelomatosis trials for patients entered since 1980","volume":"6","author":"MacLennan","year":"1988","journal-title":"Hematol Oncol"},{"key":"2025122310090516000_308.6935.1033.35","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1038\/bjc.1988.17","article-title":"A randomized trial of maintenance versus no maintenance melphalan and prednisone in responding multiple myeloma patients","volume":"57","author":"Belch","year":"1988","journal-title":"Br J Cancer"},{"key":"2025122310090516000_308.6935.1033.36","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1056\/NEJM199005173222005","article-title":"Maintenance treatment with recombinant interferon alfa-2b in patients with multiple myeloma responding to conventional induction chemotherapy","volume":"322","author":"Mandelli","year":"1990","journal-title":"N Engl J Med"},{"issue":"suppl 4","key":"2025122310090516000_308.6935.1033.37","doi-asserted-by":"crossref","first-page":"S45","DOI":"10.1016\/0277-5379(91)90571-T","article-title":"Interferon therapy during the plateau phase of multiple myeloma: an update of the Swedish study","volume":"27","author":"Westin","year":"1991","journal-title":"Eur J Cancer"},{"issue":"suppl 4","key":"2025122310090516000_308.6935.1033.38","doi-asserted-by":"crossref","first-page":"S40","DOI":"10.1016\/0277-5379(91)90570-4","article-title":"Interferon alfa-2b with VMCP compared to VMCP alone for induction and interferon alfa-2b compared to controls for remission maintenance in multiple myeloma: interim results","volume":"27","author":"Ludwig","year":"1991","journal-title":"Eur J Cancer"},{"key":"2025122310090516000_308.6935.1033.39","first-page":"55","volume":"66","author":"Selby","year":"1987","journal-title":"Multiple myeloma treated with high dose intravenous melphalan Br J Haematol"},{"key":"2025122310090516000_308.6935.1033.40","doi-asserted-by":"crossref","first-page":"1666","DOI":"10.1182\/blood.V80.7.1666.1666","article-title":"Low-risk intensive therapy for multiple myeloma with combined autologous bone marrow and blood stem cell support","volume":"80","author":"Jagannath","year":"1992","journal-title":"Blood"},{"key":"2025122310090516000_308.6935.1033.41","first-page":"139","article-title":"Connors JM, Klingermann HG, O'Reilly SE, Shepherd JD, et al. Treatment of multiple myeloma with intensive chemotherapy followed by autologous BMT using marrow purged with 4- hydroperoxycyclophosphamide","volume":"11","author":"Reece","year":"1993","journal-title":"Bone Marrow Transplant"},{"key":"2025122310090516000_308.6935.1033.42","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1182\/blood.V79.5.1130.1130","article-title":"Intensive combined therapy for previously untreated aggressive myeloma","volume":"79","author":"Attal","year":"1992","journal-title":"Blood"},{"key":"2025122310090516000_308.6935.1033.43","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1200\/JCO.1992.10.10.1569","article-title":"High- dose busulfan in patients with myeloma","volume":"10","author":"Mansi","year":"1992","journal-title":"J Clin Oncol"},{"key":"2025122310090516000_308.6935.1033.44","first-page":"125","article-title":"Maintenance treatment with recombinant alpha interferon after autologous bone marrow transplantation for aggressive myeloma in first remission after conventional induction chemotherapy","volume":"8","author":"Attal","year":"1991","journal-title":"Bone Marrow Transplant"},{"key":"2025122310090516000_308.6935.1033.45","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1182\/blood.V77.4.712.712","article-title":"Monoclonal antibody-purged autologous bone marrow transplantation therapy for multiple myeloma","volume":"77","author":"Anderson","year":"1991","journal-title":"Blood"},{"key":"2025122310090516000_308.6935.1033.46","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1038\/bjc.1980.330","article-title":"Prognostic features in the third MRC myelomatosis trial","volume":"42","year":"1980","journal-title":"Br J Cancer"},{"doi-asserted-by":"publisher","key":"2025122310090516000_308.6935.1033.47","DOI":"10.1002\/1097-0142(197509)36:3<842::AID-CNCR2820360303>3.0.CO;2-U"}],"container-title":["BMJ"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/data.bmj.org\/tdm\/10.1136\/bmj.308.6935.1033","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmj.308.6935.1033","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,23]],"date-time":"2025-12-23T18:09:15Z","timestamp":1766513355000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.bmj.com\/lookup\/doi\/10.1136\/bmj.308.6935.1033"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1994,4,16]]},"references-count":47,"journal-issue":{"issue":"6935","published-online":{"date-parts":[[1994,4,16]]},"published-print":{"date-parts":[[1994,4,16]]}},"alternative-id":["10.1136\/bmj.308.6935.1033"],"URL":"https:\/\/doi.org\/10.1136\/bmj.308.6935.1033","relation":{},"ISSN":["0959-8138","1468-5833"],"issn-type":[{"type":"print","value":"0959-8138"},{"type":"electronic","value":"1468-5833"}],"subject":[],"published":{"date-parts":[[1994,4,16]]}}}